Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer

Nobukazu Fujimoto, Katsuyuki Kiura, Nagio Takigawa, Yoshiro Fujiwara, Shinichi Toyooka, Shigeki Umemura, Masahiro Tabata, Hiroshi Ueoka, Mitsune Tanimoto

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We examined the feasibility of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer (NSCLC), retrospectively. Twenty-five patients (21 men and 4 women) with NSCLC and good performance status who were ≤ 70 years old were analyzed. The median age was 58 years. Most patients had performance status 1 (16/25), stage IV disease (18/25) and adenocarcinoma-histology (16/25). Cisplatin and docetaxel were given on day 1 and irinotecan on day 2; the cycle was repeated every 3 weeks. The objective response rate was 39.1% (95% confidence interval: 18.7-59.5%). The median survival time and actual 2-, 3-, and 5-year survival rates were 14.3 months, 32%, 20%, and 8%, respectively. Of note, only 6 patients were treated with gefitinib at the recurrence after triplet chemotherapy; of these, 4 (67%) achieved a partial response, which might result in favorable survival. Grade 3/4 toxicities consisted of neutropenia (100%), neutropenic fever (56%), nausea/vomiting (40%), and diarrhea (16%); no cases of treatment-related death occurred. Triplet chemotherapy showed impressive survival data in our clinical trial, but proved too toxic for use in treating patients with NSCLC in the clinical practice.

Original languageEnglish
Pages (from-to)33-37
Number of pages5
JournalActa Medica Okayama
Volume64
Issue number1
Publication statusPublished - 2010

Fingerprint

irinotecan
docetaxel
Chemotherapy
Non-Small Cell Lung Carcinoma
Refractory materials
Cisplatin
Cells
Drug Therapy
Histology
Poisons
Survival
Toxicity
Neutropenia
Nausea
Vomiting
Diarrhea
Adenocarcinoma
Fever
Survival Rate
Clinical Trials

Keywords

  • Cisplatin
  • Docetaxel
  • Gefitinib
  • Irinotecan
  • Triplet chemotherapy

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer. / Fujimoto, Nobukazu; Kiura, Katsuyuki; Takigawa, Nagio; Fujiwara, Yoshiro; Toyooka, Shinichi; Umemura, Shigeki; Tabata, Masahiro; Ueoka, Hiroshi; Tanimoto, Mitsune.

In: Acta Medica Okayama, Vol. 64, No. 1, 2010, p. 33-37.

Research output: Contribution to journalArticle

Fujimoto, Nobukazu ; Kiura, Katsuyuki ; Takigawa, Nagio ; Fujiwara, Yoshiro ; Toyooka, Shinichi ; Umemura, Shigeki ; Tabata, Masahiro ; Ueoka, Hiroshi ; Tanimoto, Mitsune. / Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer. In: Acta Medica Okayama. 2010 ; Vol. 64, No. 1. pp. 33-37.
@article{2e497267356541e8b3fa187775a328c7,
title = "Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer",
abstract = "We examined the feasibility of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer (NSCLC), retrospectively. Twenty-five patients (21 men and 4 women) with NSCLC and good performance status who were ≤ 70 years old were analyzed. The median age was 58 years. Most patients had performance status 1 (16/25), stage IV disease (18/25) and adenocarcinoma-histology (16/25). Cisplatin and docetaxel were given on day 1 and irinotecan on day 2; the cycle was repeated every 3 weeks. The objective response rate was 39.1{\%} (95{\%} confidence interval: 18.7-59.5{\%}). The median survival time and actual 2-, 3-, and 5-year survival rates were 14.3 months, 32{\%}, 20{\%}, and 8{\%}, respectively. Of note, only 6 patients were treated with gefitinib at the recurrence after triplet chemotherapy; of these, 4 (67{\%}) achieved a partial response, which might result in favorable survival. Grade 3/4 toxicities consisted of neutropenia (100{\%}), neutropenic fever (56{\%}), nausea/vomiting (40{\%}), and diarrhea (16{\%}); no cases of treatment-related death occurred. Triplet chemotherapy showed impressive survival data in our clinical trial, but proved too toxic for use in treating patients with NSCLC in the clinical practice.",
keywords = "Cisplatin, Docetaxel, Gefitinib, Irinotecan, Triplet chemotherapy",
author = "Nobukazu Fujimoto and Katsuyuki Kiura and Nagio Takigawa and Yoshiro Fujiwara and Shinichi Toyooka and Shigeki Umemura and Masahiro Tabata and Hiroshi Ueoka and Mitsune Tanimoto",
year = "2010",
language = "English",
volume = "64",
pages = "33--37",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "1",

}

TY - JOUR

T1 - Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer

AU - Fujimoto, Nobukazu

AU - Kiura, Katsuyuki

AU - Takigawa, Nagio

AU - Fujiwara, Yoshiro

AU - Toyooka, Shinichi

AU - Umemura, Shigeki

AU - Tabata, Masahiro

AU - Ueoka, Hiroshi

AU - Tanimoto, Mitsune

PY - 2010

Y1 - 2010

N2 - We examined the feasibility of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer (NSCLC), retrospectively. Twenty-five patients (21 men and 4 women) with NSCLC and good performance status who were ≤ 70 years old were analyzed. The median age was 58 years. Most patients had performance status 1 (16/25), stage IV disease (18/25) and adenocarcinoma-histology (16/25). Cisplatin and docetaxel were given on day 1 and irinotecan on day 2; the cycle was repeated every 3 weeks. The objective response rate was 39.1% (95% confidence interval: 18.7-59.5%). The median survival time and actual 2-, 3-, and 5-year survival rates were 14.3 months, 32%, 20%, and 8%, respectively. Of note, only 6 patients were treated with gefitinib at the recurrence after triplet chemotherapy; of these, 4 (67%) achieved a partial response, which might result in favorable survival. Grade 3/4 toxicities consisted of neutropenia (100%), neutropenic fever (56%), nausea/vomiting (40%), and diarrhea (16%); no cases of treatment-related death occurred. Triplet chemotherapy showed impressive survival data in our clinical trial, but proved too toxic for use in treating patients with NSCLC in the clinical practice.

AB - We examined the feasibility of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer (NSCLC), retrospectively. Twenty-five patients (21 men and 4 women) with NSCLC and good performance status who were ≤ 70 years old were analyzed. The median age was 58 years. Most patients had performance status 1 (16/25), stage IV disease (18/25) and adenocarcinoma-histology (16/25). Cisplatin and docetaxel were given on day 1 and irinotecan on day 2; the cycle was repeated every 3 weeks. The objective response rate was 39.1% (95% confidence interval: 18.7-59.5%). The median survival time and actual 2-, 3-, and 5-year survival rates were 14.3 months, 32%, 20%, and 8%, respectively. Of note, only 6 patients were treated with gefitinib at the recurrence after triplet chemotherapy; of these, 4 (67%) achieved a partial response, which might result in favorable survival. Grade 3/4 toxicities consisted of neutropenia (100%), neutropenic fever (56%), nausea/vomiting (40%), and diarrhea (16%); no cases of treatment-related death occurred. Triplet chemotherapy showed impressive survival data in our clinical trial, but proved too toxic for use in treating patients with NSCLC in the clinical practice.

KW - Cisplatin

KW - Docetaxel

KW - Gefitinib

KW - Irinotecan

KW - Triplet chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=77952782303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952782303&partnerID=8YFLogxK

M3 - Article

C2 - 20200582

AN - SCOPUS:77952782303

VL - 64

SP - 33

EP - 37

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 1

ER -